HRP20141233T1 - PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 - Google Patents

PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 Download PDF

Info

Publication number
HRP20141233T1
HRP20141233T1 HRP20141233AT HRP20141233T HRP20141233T1 HR P20141233 T1 HRP20141233 T1 HR P20141233T1 HR P20141233A T HRP20141233A T HR P20141233AT HR P20141233 T HRP20141233 T HR P20141233T HR P20141233 T1 HRP20141233 T1 HR P20141233T1
Authority
HR
Croatia
Prior art keywords
peptide
cell
amino acid
cancer
acid sequence
Prior art date
Application number
HRP20141233AT
Other languages
English (en)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Publication of HRP20141233T1 publication Critical patent/HRP20141233T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464434—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Claims (27)

1. Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed SEQ ID NO:376 ili 379.
2. Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:376 i 379, u kojima su 1 ili 2 aminokiseline zamijenjene, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
3. Peptid u skladu s patentnim zahtjevom 2, naznačen time što je druga aminokiselina od N-kraja u aminokiselinskom slijedu SEQ ID NO:376 ili 379 zamijenjena leucinom ili metioninom.
4. Peptid u skladu s patentnim zahtjevom 2 ili 3, naznačen time što je C-terminalna aminokiselina u aminokiselinskom slijedu SEQ ID NO:376 ili 379 zamijenjena valinom ili leucinom.
5. Peptid u skladu s patentnim zahtjevom 1, naznačen time što navedeni peptid ima aminokiselinski slijed SEQ ID NO:376 ili 379.
6. Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78.
7. Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78, u kojima je jedna aminokiselina zamijenjena, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
8. Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed u kojem je druga aminokiselina od N-kraja u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, tirozinom, metioninom ili triptofanom i/ili je C-terminalna aminokiselina u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, leucinom, izoleucinom, triptofanom ili metioninom, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
9. Peptid u skladu s patentnim zahtjevom 6, naznačen time što navedeni peptid ima aminokiselinski slijed SEQ ID NO:41, 44, 46, 48 ili 78.
10. Farmaceutski pripravak namijenjen upotrebi u liječenju ili sprječavanju raka, naznačen time što navedeni pripravak sadrži najmanje jedan peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili polinukleotid koji kodira peptid.
11. Egzosom koji na svojoj površini predočava kompleks, naznačen time što se sastoji od peptida u skladu s bilo kojim od patentnih zahtjeva 6 do 9 i HLA antigena.
12. Egzosom u skladu s patentnim zahtjevom 11, naznačen time što je HLA antigen HLA-A24.
13. Egzosom u skladu s patentnim zahtjevom 12, naznačen time što je HLA antigen HLA-A2402.
14. Egzosom koji na svojoj površini predočava kompleks, naznačen time što se sastoji od peptida u skladu s bilo kojim od patentnih zahtjeva 1 do 5 i HLA antigena.
15. Egzosom u skladu s patentnim zahtjevom 14, naznačen time što je HLA antigen HLA-A2.
16. Egzosom u skladu s patentnim zahtjevom 15, naznačen time što je HLA antigen HLA-A0201.
17. Postupak induciranja stanice za predočavanje antigena koja može inducirati citotoksičnu T-stanicu in vitro, naznačen time što se sastoji u koraku: (a) stavljanja u kontakt stanice za predočavanje antigena s peptidom u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili (b) prebacivanja gena koji sadrži polinukleotid koji kodira peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 9 u stanicu za predočavanje antigena.
18. Postupak induciranja citotoksične T-stanice in vitro, naznačen time što se sastoji u stavljanju u kontakt T-stanice s peptidom u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
19. Postupak induciranja citotoksične T-stanice in vitro, naznačen time što se sastoji u koracima: (i) stavljanja u kontakt stanice za predočavanje antigena s peptidom u skladu s bilo kojim od patentnih zahtjeva 1 do 9, i (ii) miješanja stanice za predočavanje antigena iz koraka (i) s CD8+ T-stanicom i suuzgoj.
20. Izolirana citotoksična T-stanica, naznačena time što je inducirana postupkom u skladu s patentnim zahtjevom 18 ili 19, ili što je transducirana nukleinskim kiselinama koje kodiraju polipeptidne podjedinice TCR koje se vežu s peptidom u skladu s bilo kojim od patentnih zahtjeva 1 do 9 u kontekstu HLA-A24 ili HLA-A2.
21. Stanica za predočavanje antigena, naznačena time što sadrži kompleks nastao između HLA antigena i peptida u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili što je inducirana postupkom u skladu s patentnim zahtjevom 17.
22. Cjepivo namijenjeno upotrebi u inhibiranju proliferiranja stanica koje eksprimiraju gen sa SEQ ID NO:3, naznačeno time što cjepivo sadrži najmanje jedan peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 9 kao aktivni sastojak.
23. Cjepivo u skladu s patentnim zahtjevom 22, naznačeno time što su stanice koje eksprimiraju gen sa SEQ ID NO:3 stanice raka.
24. Peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili polinukleotid koji kodira navedeni peptid, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju raka.
25. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, cjepivo u skladu s patentnim zahtjevom 23, ili peptid ili polinukleotid u skladu s patentnim zahtjevom 24, naznačeni time što se rak bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, kolorektalni rak, endometrioza, rak jednjaka, rak želuca; difuzni tip raka želuca, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, rak gušterače, rak prostate, karcinom bubrega, SCLC, tumor mekog tkiva i tumor testisa.
26. Cjepivo u skladu s patentnim zahtjevom 25, naznačeno time što je formulirano za primjenu na subjektu čiji HLA antigen je HLA-A24 ili HLA-A2.
27. Postupak identificiranja peptida koji može inducirati citotoksičnu T-stanicu protiv stanice koja eksprimira EphA4, naznačen time što se navedeni postupak sastoji u koracima: (i) osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78; (ii) biranja slijeda kandidat koji nema značajnu homologiju s peptidima koji se dobivaju iz produkata bilo kojeg poznatog ljudskog gena koji nije EphA4; (iii) stavljanja u kontakt peptida koji ima slijed kandidat nabrojan u koraku (ii) sa stanicom za predočavanje antigena; (iv) stavljanja u kontakt stanice za predočavanje antigena iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da simulira T-stanicu; i (v) identificiranja peptida čija je inducibilnost citotoksične T-stanice ista kao ili veća nego kod peptida koji ima izvorni aminokiselinski slijed.
HRP20141233AT 2007-02-21 2014-12-17 PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 HRP20141233T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21
EP12151711.4A EP2465864B1 (en) 2007-02-21 2008-02-21 EphA4 derived peptide vaccines

Publications (1)

Publication Number Publication Date
HRP20141233T1 true HRP20141233T1 (hr) 2015-02-27

Family

ID=39709837

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20131044AT HRP20131044T1 (hr) 2007-02-21 2013-11-05 Peptidna cjepiva za oblike raka koji eksprimiraju tumorski vezane antigene
HRP20141233AT HRP20141233T1 (hr) 2007-02-21 2014-12-17 PEPTIDNA CJEPIVA DOBIVENA IZ EphA4
HRP20150108TT HRP20150108T1 (hr) 2007-02-21 2015-01-28 Peptidna cjepiva za rak koji eksprimira tumoru pridružene antigene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20131044AT HRP20131044T1 (hr) 2007-02-21 2013-11-05 Peptidna cjepiva za oblike raka koji eksprimiraju tumorski vezane antigene

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20150108TT HRP20150108T1 (hr) 2007-02-21 2015-01-28 Peptidna cjepiva za rak koji eksprimira tumoru pridružene antigene

Country Status (28)

Country Link
EP (20) EP2465864B1 (hr)
JP (6) JP5239103B2 (hr)
KR (8) KR20160045939A (hr)
CN (4) CN103351423B (hr)
AR (1) AR068302A1 (hr)
AU (1) AU2008218463B2 (hr)
BR (1) BRPI0808421B1 (hr)
CA (3) CA2992074C (hr)
CO (1) CO6190536A2 (hr)
CY (2) CY1114590T1 (hr)
DK (3) DK2121731T3 (hr)
ES (6) ES2540893T3 (hr)
HK (7) HK1172042A1 (hr)
HR (3) HRP20131044T1 (hr)
IL (10) IL200478A (hr)
MX (4) MX359680B (hr)
MY (2) MY173379A (hr)
NZ (4) NZ579768A (hr)
PH (1) PH12014501642A1 (hr)
PL (3) PL2121731T3 (hr)
PT (2) PT2121731E (hr)
RU (1) RU2464275C2 (hr)
SG (3) SG10201909675QA (hr)
SI (3) SI2121731T1 (hr)
TW (5) TWI615403B (hr)
UA (1) UA100372C2 (hr)
WO (1) WO2008102557A1 (hr)
ZA (1) ZA200905881B (hr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019475A2 (en) 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
ES2632123T3 (es) * 2007-08-20 2017-09-11 Oncotherapy Science, Inc. Péptido CDH3 y agente medicinal que comprende el mismo
RU2011103199A (ru) 2008-06-30 2012-08-10 Онкотерапи Сайенс, Инк. (Jp) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
CA2741399C (en) * 2008-10-22 2016-10-11 Oncotherapy Science, Inc. Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
CN102333867B (zh) 2008-12-24 2015-01-14 肿瘤疗法科学股份有限公司 C1orf59肽及包含它的疫苗
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
TW201627003A (zh) * 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
US9125849B2 (en) * 2010-12-02 2015-09-08 Oncotherapy Science, Inc. TOMM34 peptides and vaccines including the same
CN104144707B (zh) 2011-12-14 2018-09-14 得克萨斯系统大学董事会 用于癌症疗法的连带基因失活生物标志和靶标
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
JP6259983B2 (ja) * 2012-07-10 2018-01-17 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン
WO2014010232A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
DK2891663T3 (en) 2012-08-31 2018-03-26 Vasculead Inc PSF1-Derived Peptide
EP2895600B1 (en) 2012-09-11 2020-02-19 OncoTherapy Science, Inc. Ube2t peptides and vaccines containing the same
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
JPWO2015005479A1 (ja) * 2013-07-12 2017-03-02 大日本住友製薬株式会社 腫瘍抗原ペプチド
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
RU2700881C2 (ru) 2014-08-04 2019-09-23 Онкотерапи Сайенс, Инк. Пептид, полученный из urlc10, и содержащая его вакцина
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
HRP20220605T1 (hr) 2017-01-25 2022-07-08 Ose Immunotherapeutics Postupak za proizvodnju stabilne emulzije za isporuku peptida
EP3601539A4 (en) * 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES
US11969463B2 (en) * 2017-08-10 2024-04-30 Good T Cells, Inc. Method for activating T cells for cancer treatment
CN112812154B (zh) * 2018-02-15 2022-04-05 国立大学法人旭川医科大学 癌症抗原肽
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL103928A0 (en) * 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
JPH09512167A (ja) * 1994-04-15 1997-12-09 アムジエン・インコーポレーテツド Ｈｅｋ５、ｈｅｋ７、ｈｅｋ８、ｈｅｋ１１、新規なｅｐｈ様受容体タンパク質チロシンキナーゼ
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
ATE319477T1 (de) 1995-08-03 2006-03-15 Univ Leiden Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
WO1999018126A1 (fr) * 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU1220001A (en) * 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
AU2001278070A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Basal cell markers in breast cancer and uses thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
US20040236091A1 (en) * 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005536186A (ja) * 2002-03-07 2005-12-02 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管および血管内皮細胞遺伝子
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
EP1594447A2 (en) * 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2507924A1 (en) * 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005019475A2 (en) * 2003-08-20 2005-03-03 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
EP1730279A2 (en) * 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
EP2520652B1 (en) * 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
JP2008509654A (ja) * 2004-06-01 2008-04-03 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
CA2598889A1 (en) * 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
EP2325306B1 (en) * 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
EP1930427B1 (en) * 2005-08-09 2012-04-11 Kurume University Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule
KR101304243B1 (ko) * 2005-08-09 2013-09-05 온코세라피 사이언스 가부시키가이샤 ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
WO2007064743A2 (en) * 2005-11-30 2007-06-07 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP5290148B2 (ja) * 2006-04-10 2013-09-18 ジェネンテック， インコーポレイテッド Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子
CN105418751B (zh) * 2006-06-16 2019-03-05 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
US20090081659A1 (en) * 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
ES2632123T3 (es) * 2007-08-20 2017-09-11 Oncotherapy Science, Inc. Péptido CDH3 y agente medicinal que comprende el mismo
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
CA2775978A1 (en) * 2009-09-29 2011-04-07 Protagen Ag Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof

Also Published As

Publication number Publication date
CN104292299A (zh) 2015-01-21
WO2008102557A1 (en) 2008-08-28
TWI596109B (zh) 2017-08-21
NZ602122A (en) 2014-03-28
EP2465867A2 (en) 2012-06-20
EP2465864A3 (en) 2012-10-03
ES2527397T3 (es) 2015-01-23
ES2532708T3 (es) 2015-03-31
IL219044A (en) 2014-12-31
IL219048A (en) 2015-07-30
KR20160045939A (ko) 2016-04-27
IL200478A (en) 2015-11-30
EP2476693B1 (en) 2014-12-24
JP2013116895A (ja) 2013-06-13
EP2465865B1 (en) 2016-11-02
EP2465867B1 (en) 2015-04-01
ES2435194T3 (es) 2013-12-16
EP2567971A2 (en) 2013-03-13
EP2594582A3 (en) 2013-08-14
CN103351423A (zh) 2013-10-16
JP5614761B2 (ja) 2014-10-29
IL219042A (en) 2016-03-31
PH12014501642B1 (en) 2015-12-02
EP2570428A2 (en) 2013-03-20
IL219045A0 (en) 2012-05-31
HK1134507A1 (en) 2010-04-30
ES2541863T3 (es) 2015-07-27
CN104292299B (zh) 2017-09-29
JP5239104B2 (ja) 2013-07-17
EP2594581A2 (en) 2013-05-22
IL219040A0 (en) 2012-05-31
HK1172344A1 (en) 2013-04-19
UA100372C2 (ru) 2012-12-25
MY173379A (en) 2020-01-21
BRPI0808421A2 (pt) 2017-08-29
AU2008218463A1 (en) 2008-08-28
IL219043A0 (en) 2012-05-31
EP2570429A3 (en) 2013-08-28
EP2476695A3 (en) 2012-12-12
IL219040A (en) 2014-12-31
CN103351423B (zh) 2016-09-28
TW201538522A (zh) 2015-10-16
KR20150018895A (ko) 2015-02-24
EP2476692B1 (en) 2015-04-15
MX2009009022A (es) 2010-03-03
MX337417B (es) 2016-03-03
EP2573110A2 (en) 2013-03-27
EP2476694B1 (en) 2014-11-19
TWI610939B (zh) 2018-01-11
AU2008218463B2 (en) 2013-01-17
EP2567971A3 (en) 2013-06-26
ES2530777T3 (es) 2015-03-05
CA2992074A1 (en) 2008-08-28
EP2476692A3 (en) 2012-12-19
CA2992074C (en) 2021-01-05
TW201433574A (zh) 2014-09-01
PH12014501642A1 (en) 2015-12-02
EP2476694A3 (en) 2013-04-24
KR20140121489A (ko) 2014-10-15
EP2570430A2 (en) 2013-03-20
IL219042A0 (en) 2012-05-31
EP2465867A3 (en) 2012-10-10
CA2678755C (en) 2016-04-26
EP2476692A2 (en) 2012-07-18
HK1172041A1 (en) 2013-04-12
EP2121731B1 (en) 2013-08-14
MX337456B (es) 2016-03-03
EP2573110A3 (en) 2013-09-04
JP2010519176A (ja) 2010-06-03
SI2476694T1 (sl) 2015-02-27
HRP20131044T1 (hr) 2013-12-06
JP5608953B2 (ja) 2014-10-22
KR101511140B1 (ko) 2015-04-10
IL219046A (en) 2015-02-26
CY1114590T1 (el) 2016-10-05
KR101644877B1 (ko) 2016-08-03
EP2570430A3 (en) 2013-07-10
KR20150064236A (ko) 2015-06-10
EP2570428A3 (en) 2013-07-10
IL219046A0 (en) 2012-05-31
SG179402A1 (en) 2012-04-27
IL219041A0 (en) 2012-05-31
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
KR101543623B1 (ko) 2015-08-11
IL200478A0 (en) 2010-04-29
EP2570429A2 (en) 2013-03-20
TWI615403B (zh) 2018-02-21
JP5874158B2 (ja) 2016-03-02
KR20150116463A (ko) 2015-10-15
EP2476694A2 (en) 2012-07-18
ZA200905881B (en) 2010-05-26
IL219043A (en) 2014-12-31
TW201623325A (zh) 2016-07-01
EP2121731A4 (en) 2010-04-21
EP2476693A3 (en) 2012-10-03
EP2465865A2 (en) 2012-06-20
KR20130023407A (ko) 2013-03-07
CN101663315A (zh) 2010-03-03
PT2465864E (pt) 2015-01-14
TWI494319B (zh) 2015-08-01
PL2476694T3 (pl) 2015-04-30
SI2465864T1 (sl) 2014-12-31
NZ602119A (en) 2014-03-28
MX359680B (es) 2018-09-28
EP2583976A3 (en) 2013-10-23
ES2540893T3 (es) 2015-07-14
DK2476694T3 (en) 2014-12-08
EP2121731A1 (en) 2009-11-25
CN101663315B (zh) 2014-10-15
PL2465864T3 (pl) 2015-03-31
EP2594581A3 (en) 2013-08-14
KR101644871B1 (ko) 2016-08-02
MY155029A (en) 2015-08-28
CO6190536A2 (es) 2010-08-19
TW200844111A (en) 2008-11-16
EP2465865A3 (en) 2013-07-24
HRP20150108T1 (hr) 2015-05-08
EP2573109A3 (en) 2013-06-19
HK1172043A1 (en) 2013-04-12
EP2465864B1 (en) 2014-10-08
JP2010209060A (ja) 2010-09-24
EP2594582A2 (en) 2013-05-22
KR20140130507A (ko) 2014-11-10
BRPI0808421B1 (pt) 2021-10-05
SI2121731T1 (sl) 2013-10-30
EP2583976A2 (en) 2013-04-24
EP2565203A1 (en) 2013-03-06
EP2574623A2 (en) 2013-04-03
PT2121731E (pt) 2013-10-24
EP2465864A2 (en) 2012-06-20
HK1172346A1 (en) 2013-04-19
CA2919248A1 (en) 2008-08-28
EP2574623A3 (en) 2013-07-17
EP2476693A2 (en) 2012-07-18
IL219047A0 (en) 2012-05-31
SG10201909675QA (en) 2019-11-28
DK2465864T3 (en) 2014-11-24
IL219044A0 (en) 2012-05-31
JP2013091645A (ja) 2013-05-16
IL219041A (en) 2014-12-31
EP2465866A3 (en) 2012-10-10
NZ579768A (en) 2012-03-30
SG10201506589WA (en) 2015-09-29
KR101511134B1 (ko) 2015-04-28
KR20090121349A (ko) 2009-11-25
JP5239103B2 (ja) 2013-07-17
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
HK1172345A1 (en) 2013-04-19
EP2573109A2 (en) 2013-03-27
HK1172042A1 (zh) 2013-04-12
RU2464275C2 (ru) 2012-10-20
JP2016094459A (ja) 2016-05-26
DK2121731T3 (da) 2013-10-21
KR101540000B1 (ko) 2015-07-29
JP2014210804A (ja) 2014-11-13
EP2476695A2 (en) 2012-07-18
EP2465866A2 (en) 2012-06-20
TWI438207B (zh) 2014-05-21
TW201422637A (zh) 2014-06-16
PL2121731T3 (pl) 2014-01-31
NZ591704A (en) 2012-09-28
IL219048A0 (en) 2012-05-31
CY1115841T1 (el) 2017-01-25
AR068302A1 (es) 2009-11-11
RU2009135020A (ru) 2011-03-27

Similar Documents

Publication Publication Date Title
HRP20141233T1 (hr) PEPTIDNA CJEPIVA DOBIVENA IZ EphA4
JP2010519176A5 (hr)
JP2010506826A5 (hr)
RU2009118432A (ru) Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
JP2008530975A5 (hr)
RU2009141595A (ru) Пептиды тем8 и содержащие их вакцины
RU2011110376A (ru) Эпитопные пептиды hig2 и urlc10 и содержание их вакцины
RU2011138160A (ru) Пептиды foxmi и вакцины, содержащие их
JP2012517799A5 (hr)
JP2012520659A5 (hr)
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
JP2013523084A5 (hr)
RU2009129531A (ru) Вакцины на основе пептида foxp3
JP2013517764A5 (hr)
RU2014121502A (ru) Пептиды торк и содержащие их вакцины
JP2015529219A5 (hr)
JP2011529683A5 (hr)
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
JP2012527867A5 (hr)
RU2018116851A (ru) Пептид, полученный из foxm1, и включающая его вакцина
RU2011120447A (ru) Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
JP2012526519A5 (hr)
JP2014506114A5 (hr)
RU2017106887A (ru) Пептид, полученный из koc1, и содержащая его вакцина